<DOC>
	<DOC>NCT00686595</DOC>
	<brief_summary>This study will evaluate the efficacy, tolerability, and effect on the quality of life of infliximab in adults with moderate-to-severe psoriasis who are resistant to etanercept after 12 weeks of treatment or have failed 24 weeks of treatment with etanercept. Infliximab will be administered as an intravenous infusion of 5 mg/kg at Baseline (Week 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 6 (Week 14), and Visit 8 (Week 22).</brief_summary>
	<brief_title>A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>&gt;=18 to 75 years of age at Screening, either sex, and any race. Diagnosis of moderatetosevere plaque psoriasis &gt;6 months prior to Screening. Resistant (after 12 weeks) or failed 24 weeks of etanercept treatment. Not reached PASI 75 at Screening Visit after 24 weeks of etanercept treatment or resistant to etanercept. Agree to avoid prolonged sun exposure or artificial ultraviolet light sources during study. Satisfy requirements of Screening and tuberculosis (TB) test as specified in protocol. Chest xray at Visit 1 or within 3 months prior to Visit 1 with no evidence of malignancy, infection, or fibrosis. Laboratory tests must be within protocolspecified parameters. Free of any clinically significant disease that would interfere with study evaluations. Willing to participate and adhere to study procedures by signing written informed consent. Women of childbearing potential and all men must be using adequate birth control measures and continue to do so until 6 months after receiving last dose of study medication. Females of childbearing potential must have negative serum pregnancy test at Visit 1 and negative urine pregnancy test at Visit 2. Achieve PASI 75 or have BSA &lt;10% after 24 weeks of etanercept. Current druginduced psoriasis. Females who are pregnant or nursing and both males and females who are planning pregnancy during study period or during 6 months after receiving last dose of study medication. Previously treated with infliximab. Currently taking or have taken protocolspecified prohibited drugs within specified time frame prior to Baseline. Congestive Heart Failure (CHF) Chronic or recurrent infectious disease. Have or have had serious infection, or been hospitalized or received IV antibiotics for this infection during the 2 months prior to Visit 1. Have or have had opportunistic infection within 6 months prior to Visit 1. Have or have had herpes zoster infection within 2 months prior to Visit 1. Human Immunodeficiency Virus (HIV), hepatitis B or C. History of any clinically significant adverse events (AEs) to murine or chimeric proteins or human/murine recombinant products. Current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral, or psychiatric disease. History of demyelinating disease or symptoms suggestive of multiple sclerosis or optic neuritis. Current signs and symptoms or history of systemic lupus erythematosus. Transplanted organ (exception corneal transplant &gt;3 months prior to Visit 1). History of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location. Malignancy within previous 5 years (exception basal cell carcinoma of skin that has been treated with no evidence of recurrence). Unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to veins. Have had substance abuse (drug or alcohol) problem within previous 3 years. History of any clinically significant adverse reactions (including allergic reactions) to paracetamol/acetaminophen or histamine H1 receptor antagonist. In a situation or have a condition that, in opinion of investigator, may interfere with optimal participation in study. Used investigational drugs within 4 weeks of Screening. Participating in any other clinical study. Staff personnel directly involved with this study. Family members of investigational study staff.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>